Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology

Sanofi25 enrolled

Overview

Primary objective was to determine efficacy of Alfuzosin in the treatment of children and adolescents 2-16 years of age with newly diagnosed or progressive hydronephrosis due to elevated detrusor Leak Point Pressure \[LPP\] of neuropathic etiology. Secondary objectives were: * To investigate the safety and tolerability of alfuzosin 0.2 mg/kg/day in children and adolescents, * To investigate the number of Urinary Tract Infection (UTI) episodes, * To investigate the pharmacokinetics of Alfuzosin (population kinetics).

The study consisted of 2 phases: * a 12-week efficacy phase then, * a 40-week safety extension phase. All eligible subjects received alfuzosin 0.2 mg/kg/day. The formulation and the frequency was assigned by Interactive Voice Response System (IVRS) according to age group and ability to swallow tablets. Patients who completed the 12-week open-label treatment period were offered to continue in the 40-week open-label safety extension study. The treatment was the same as in the 12-week efficacy phase. All patients had a one-week follow-up period after the last dose intake.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hydronephrosis Neurogenic Bladder

Interventions

AlfuzosinDRUG

Dose: 0.2 mg/kg/day Route: oral

Eligibility

Sex: ALLMin age: 2 YearsMax age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Children and adolescents of either gender 2 - 16 years of age with a detrusor Leak Point Pressure (LPP) of 40 cm water or greater and with newly diagnosed or progressive hydronephrosis either Society of Fetal Urology (SFU) grade 1, 2 or 3 due to neuropathic bladder dysfunction. Exclusion Criteria: * Hydronephrosis of non-neuropathic etiology. * Urological surgery in the last 4 months prior to the study. * Urethral dilatation in the last 3 months prior to the baseline urodynamic assessment. * α-blocker therapy in the last 4 weeks prior to the baseline urodynamic assessment. * Detrusor injections of botulinum toxin in the last 6 months. * Urological diseases/conditions other than functional bladder obstruction of neuropathic etiology, that can lead to upper urinary tract dilatation (e.g., bladder anomalies, ureterocele). * History of intolerance to α-blocker therapy. * Orthostatic hypotension. * History of risk factors for Torsade de pointes (e.g., family history of Long QT Syndrome). The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (12)

Sanofi-Aventis Administrative Office

Sofia, Bulgaria

Sanofi-Aventis Administrative Office

Laval, Canada

Sanofi-Aventis Administrative Office

Tallinn, Estonia

Outcomes

Primary Outcomes

Number of Participants With a Decrease From Baseline ≥ 1 in the Society of Fetal Urology (SFU) Grade of Hydronephrosis

Hydronephrosis was investigated by ultrasound and graded using SFU classification at each time point. 'Complete response' was assessed when bilateral hydronephrosis at baseline and grade decrease from baseline ≥ 1 for both kidneys, or, unilateral hydronephrosis at baseline and grade decrease from baseline ≥ 1 for the affected kidney without worsening of the other kidney. 'Partial response' was assessed when bilateral hydronephrosis at baseline and grade decrease from baseline ≥ 1 for one kidney without worsening of the other kidney.

Time frame: baseline and 12 weeks (efficacy study phase)

Secondary Outcomes

Number of Participants With Symptomatic Urinary Tract Infection (UTI) Episodes

When a patient presented with symptoms such as pain, fever or hematuria (discretion of the Investigator), an urinalysis was performed including a dipstick and a quantitative urine culture. A symptomatic UTI was defined as the presence of symptoms and a positive culture with \> 100 000 Colony Forming Units (CFUs) with a single organism.

Time frame: 12 weeks (efficacy study phase)

Number of Participants With Symptomatic Urinary Tract Infection (UTI) Episodes

Time frame: 52 weeks (efficacy and extension study phases)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.